3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
86
Colonic Neoplasms
32
Rectal Neoplasms
31
Neoplasms
24
Pancreatic Neoplasms
22
Stomach Neoplasms
20
Neoplasm Metastasis
20
Esophageal Neoplasms
20
Neuroblastoma
12
Glioma
11
Sarcoma
9
Glioblastoma
9
Small Cell Lung Carcinoma
8
Carcinoma, Non-Small-Cell Lung
8
Brain Neoplasms
8
Adenocarcinoma Of Esophagus
8
Rhabdomyosarcoma
7
Lung Neoplasms
7
Sarcoma, Ewing
6
Gliosarcoma
6
Esophageal Squamous Cell Carcinoma
6
Medulloblastoma
5
Central Nervous System Neoplasms
5
Breast Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Intestinal Neoplasms
4
Gastrointestinal Neoplasms
4
Digestive System Neoplasms
4
Digestive System Diseases
4
Adenocarcinoma
4
Interventions
pembrolizumab
3
Nivolumab
2
vicriviroc
1
spartalizumab
1
relatlimab
1
copanlisib
1
binimetinib
1
Oxaliplatin
1
Leucovorin
1
Irinotecan
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Spinocerebellar Degenerations
×
Irinotecan
×
Clear all
NCT03374254
2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1
Completed
116 enrolled
18 charts